Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H+/K+-ATPase.
10.4062/biomolther.2015.052
- Author:
In Young HWANG
1
;
Choon Sik JEONG
Author Information
1. College of Pharmacy, Duksung Women's University, Seoul 132-714, Republic of Korea. choonsik@duksung.ac.kr
- Publication Type:Original Article
- Keywords:
Sennoside A;
Sennoside B;
Prostaglandin E2;
H+/K+-ATPase;
Gastric lesion
- MeSH:
Animals;
Dinoprostone*;
Gastric Acid;
Gastric Emptying;
Gastric Juice;
Gastritis;
Glycosides;
Hydrogen-Ion Concentration;
Models, Animal;
Proton Pumps;
Rats;
Stomach Diseases;
Stomach Ulcer;
Up-Regulation*
- From:Biomolecules & Therapeutics
2015;23(5):458-464
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sennoside A (erythro) and sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer. To elucidate their gastroprotective effects, the inhibitions of HCl*EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H+/K+-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and sennoside B accelerated motility. Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.
